Navigation Links
Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights
Date:2/26/2009

' Form 10-K for the year ended December 31, 2007 and Anadys' Form 10-Q for the quarter ended September 30, 2008. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

    Condensed Consolidated Financial Statements

                           Anadys Pharmaceuticals, Inc.
                Condensed Consolidated Statements of Operations
                    (In thousands except per share amounts)
                                   (Unaudited)

                                    Three Months Ended   Twelve Months Ended
                                         December 31,        December  31,
                                        2008      2007      2008      2007

    Revenues                              $-      $225        $-   $24,118

    Operating expenses
      Research and development (1)     6,902     6,917    25,993    28,192
      General and administrative       2,005     1,847     8,109     8,692
    Total operating expenses (2)       8,907     8,764    34,102    36,884

    Interest income and other, net       389       739     1,700     3,594

    Net loss (2)                     $(8,518)  $(7,800) $(32,402)  $(9,172)

    Net loss per share, basic and
     diluted (2)                      $(0.30)   $(0.27)   $(1.13)   $(0.32)

    Share used in calculating net
     loss per share, basic and
     diluted                          28,797    28,674    28,750    28,646


    (1)  Includes $36 as additional research and development expense, which
         represents an estimate of the net payable due to Novartis of
         ANA975 research and development costs for the three months ended
         December 31, 2007.  Includes ($50) a
'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Anadys Pharmaceuticals to Present at BIO InvestorForum 2007
2. Anadys Pharmaceuticals to Present at Bio Investor Forum
3. Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
4. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
5. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2008 Financial Results
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Johnson & Johnson and its ... lawsuit ( http://www.risperdallawsuit2014.com/ ) settlement with a California ... use of the antipsychotic medication. According to court ... third bellwether trial to involve male breast growth ... Pennsylvania’s Philadelphia Court of Common Pleas, where more ...
(Date:5/29/2015)... May 29, 2015 A group of doctors ... joined the national effort to teach this “new math” to ... U.S. have been “sickened” by the recent implementation of Common ... or hate it, Common Core is now a reality in ... Parents are now seeking ways to improve common core ...
(Date:5/29/2015)... FL (PRWEB) May 29, 2015 ... Utah, recently partnered with Stratus Video ... which will facilitate better communication and timely ... (LEP) and hearing loss. Stratus’ video remote ... in-house translators, enabling staff to quickly access ...
(Date:5/29/2015)... 29, 2015 The print component of ... circulation of approximately 250,000 and an estimated readership of ... vast social media strategy, and across a network of ... digital version of the campaign, click here. ... publication. Inside, the actress, model and producer details her ...
(Date:5/29/2015)... New York, NY (PRWEB) May 29, 2015 ... readers on the “beauty of protection”. Skin Health ... through USA Today within the markets of New York, ... reach an estimated 750,000 readers. Its digital counterpart will ... online content hubs. To read more the Skin Health ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 3Health News:Doctors Discover a Cure for the Common Core 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 3Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 4Health News:Mediaplanet Launches “Skin Health” Campaign Featuring Colorescience 2
... According to a new study it is observed that ... effects for adults diagnosed with bacterial meningitis. Dexamethasone is ... patients.// The death rate among adults diagnosed with bacterial ... pneumonia. Researchers from the Academic Medical Center in Amsterdam ...
... to a new study researchers observe that stress hormones ... HPA (hypothalamus-pituitary-adrenal) axis is a hormonal system that helps ... end result is the production of the stress hormone ... is characterized by aches, pains and overwhelming tiredness. It's ...
... that a new topical medication can effectively treat signs of ... that in a long-term study of tazarotene cream, has ... 55 percent// of those tested, and it continued to show ... radiation from the sun is known to have numerous ill ...
... University observed that a chest compression belt outperforms manual ... someone has a cardiac arrest, it's vital to get ... as possible. Usually this is done by applying chest ... but these are usually not available in those vital ...
... in University of Boston observe that brain imaging sheds new ... apnoea, a person stops breathing, momentarily, many times during the ... at the back of the throat, causing upper airway obstruction. ... daytime sleepiness. It may also be a risk factor for ...
... emphysema does not help the sickest patients, according to ... lungs - the alveoli - are progressively destroyed,// leaving ... do everyday activities like climbing stairs or carrying their ... lung reduction surgery was beneficial for people with emphysema. ...
Cached Medicine News:
(Date:5/29/2015)... MENLO PARK, Calif. , May 29, ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical ... therapies in new orphan drug indications, presented additional ... Cancer Research (AACR) Advances in Brain Cancer Research ... product candidate VAL-083 (dianhydrogalactitol) to treat ...
(Date:5/29/2015)... 2015 Educating the community continues to ... the Advancement of Wound Care (AAWC), which was ... AAWC,s corporate partners, the Association provides medical professionals ... AAWC website at http://aawconline.org/education-for-the-generalist/ . The portal ... links to various CME/CEU educational programs. This education ...
(Date:5/28/2015)... , May 28, 2015 ... has announced the addition of Jain PharmaBiotech,s ... Companies"  to their offering.  ... (RNAi) or gene silencing involves the use ... the cell, this material is processed into ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5The Association for the Advancement of Wound Care Educates the Public 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3
... N.Y., July 17 Strong National,Museum of Play ... of the,American Journal of Play, the first interdisciplinary ... The inaugural issue enters the scholarly scene ... the most prominent national,researchers and writers in the ...
... to data from other, technologies -, ... Bradmer Pharmaceuticals Inc.,(TSX: BMR), a biopharmaceutical company dedicated ... released progression free,survival (PFS) data from two previously ... (GBM) patients. As an exploratory,endpoint of the single ...
Cached Medicine Technology:Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008 2Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials 2Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials 3Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials 4Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: